Antibiotic complex obtained from Streptomyces bambergiensis containing mainly Moenomycins A and C. They are used as feed additives and growth promoters for poultry, swine, and cattle.

Gene disruption studies of penicillin-binding proteins 1a, 1b, and 2a in Streptococcus pneumoniae. (1/26)

The effects of inactivation of the genes encoding penicillin-binding protein 1a (PBP1a), PBP1b, and PBP2a in Streptococcus pneumoniae were examined. Insertional mutants did not exhibit detectable changes in growth rate or morphology, although a pbp1a pbp1b double-disruption mutant grew more slowly than its parent did. Attempts to generate a pbp1a pbp2a double-disruption mutant failed. The pbp2a mutants, but not the other mutants, were more sensitive to moenomycin, a transglycosylase inhibitor. These observations suggest that individually the pbp1a, pbp1b, and pbp2a genes are dispensable but that either pbp1a or pbp2a is required for growth in vitro. These results also suggest that PBP2a is a functional transglycosylase in S. pneumoniae.  (+info)

A simple screen for murein transglycosylase inhibitors. (2/26)

A simple assay for detection of compounds that bind to the active site in the transglycosylation domain of the essential bifunctional transglycosylase and transpeptidase penicillin-binding proteins (PBPs) is reported. The method is based on a competition with the specific transglycosylase inhibitor moenomycin. With moenomycin coupled to Affi-Gel beads, a simple filtration procedure allows the amount of labeled PBPs that bind to moenomycin beads in the presence of test substances to be determined. The PBPs can easily be labeled by the covalent binding of penicillin derivatives. Crude membrane extracts can be used as a source for the PBPs, and different kinds of labels for the penicillin-PBP complexes can be used. The assay can be adapted to high-throughput screens.  (+info)

Impact of flavophospholipol and vancomycin on conjugational transfer of vancomycin resistance plasmids. (3/26)

The influence of vancomycin and flavophospholipol (FPL) on the transfer rate of conjugative plasmids harboring the vancomycin resistance operon vanA was determined in several clinical and animal isolates of Enterococcus faecium. FPL significantly inhibited the frequency of transfer of conjugative VanA plasmids up to 70-fold. Vancomycin had no significant effect on the transfer rate of VanA plasmids.  (+info)

Influence of different medium components on the in vitro activity of the growth-promoting antibiotic flavomycin against enterococci. (4/26)

The growth-promoting antibiotic flavomycin (also called bambermycin, flavophospholipol and moenomycin) has a complex spectrum of activity against enterococci, with some species being naturally resistant and others susceptible. In this study, proteins added to Mueller-Hinton II medium had a strong deleterious effect on the activity of flavomycin, glucose had no effect and starch decreased the activity of flavomycin. The fatty substances Tween 80 and tributyrin increased the activity of flavomycin for several enterococcal species. Slight differences in the composition of the susceptibility test medium affected the MIC results obtained, indicating that strict standardization of the test medium is necessary.  (+info)

Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase. (5/26)

Moenomycin is a natural product glycolipid that inhibits the growth of a broad spectrum of Gram-positive bacteria. In Escherichia coli, moenomycin inhibits peptidoglycan synthesis at the transglycosylation stage, causes accumulation of cell-wall intermediates, and leads to lysis and cell death. However, unlike Esc. coli, where 5-6 log units of killing are observed, 0-2 log units of killing occurred when Gram-positive bacteria were treated with similar multiples of the MIC. In addition, bulk peptidoglycan synthesis in intact Gram-positive cells was resistant to the effects of moenomycin. In contrast, synthetic disaccharides based on the moenomycin disaccharide core structure were identified that were bactericidal to Gram-positive bacteria, inhibited cell-wall synthesis in intact cells, and were active on both sensitive and vancomycin-resistant enterococci. These disaccharide analogues do not inhibit the formation of N:-acetylglucosamine-ss-1, 4-MurNAc-pentapeptide-pyrophosphoryl-undecaprenol (lipid II), but do inhibit the polymerization of lipid II into peptidoglycan in Esc. coli. In addition, cell growth was required for bactericidal activity. The data indicate that synthetic disaccharide analogues of moenomycin inhibit cell-wall synthesis at the transglycosylation stage, and that their activity on Gram-positive bacteria differs from moenomycin due to differential targeting of the transglycosylation process. Inhibition of the transglycosylation process represents a promising approach to the design of new antibacterial agents active on drug-resistant bacteria.  (+info)

Effects of flavophospholipol on resistance in fecal Escherichia coli and enterococci of fattening pigs. (6/26)

A "plasmid-curing effect" of multiresistant Escherichia coli by flavophospholipol, an antibiotic used as an antimicrobial growth promoter (AMGP) in animal feeds, has been reported to occur in vitro and in vivo under experimental conditions. In this study, the effect of flavophospholipol under field conditions was studied. The prevalence and degree (proportion of resistant strains to the total numbers present per gram of feces) of resistance of indicator bacteria, E. coli and enterococci, was determined in fecal samples from three groups of pigs that were fed a commercial finisher feed without any AMGP. Group A was the negative control group without any AMGP, group B received the same feed with 9 mg of flavophospholipol/kg of feed (study group), and group C received the same feed with 15 mg of avoparcin/kg (positive control). Fecal samples from each pig were collected at the start and at the end of the study and assessed for the prevalence and degree of resistance against antibiotics commonly used either for therapy in pig medicine or as an AMGP. Before the start of the study, all pigs were colonized with multiresistant E. coli by mixing three resistant pig isolates through their feed after disturbance of the colonization resistance of the intestinal flora by a 3-day course of lincomycin and spectinomycin. At the end of the study, the overall prevalence and degree of resistance of E. coli in the fecal flora had increased significantly in groups A and C but remained at the same level as at the start of the study in group B. The prevalence of vancomycin resistance was 44 and 41% in groups A and B, respectively, but only very low numbers of vancomycin-resistant enterococci (VRE) per gram of feces were found. In the avoparcin-fed group, the prevalence was 72%, and in 57% of the samples, more than 50% of all enterococci present were vancomycin resistant. The prevalence of resistant Enterococcus faecalis increased only in the flavophospholipol-exposed group, from 23% before the start of the study to 43% at the end of the study. It was concluded that flavophospholipol effectively suppressed the augmentation and dissemination of multiresistant E. coli in the intestinal flora of fattening pigs. Avoparcin use strongly selected for VRE carriage and excretion. Therefore, as neither flavophospholipol nor any related molecule is used therapeutically, no cross-resistance with therapeutic antibiotics exists and no transmissible resistance has been shown; the major decrease in resistance in intestinal E. coli of flavophospholipol-fed animals seemed to outweigh the small increase in the risk of transfer of flavophospholipol-resistant E. faecalis from animals to humans via the food chain.  (+info)

Effect of feeding the ionophores monensin and laidlomycin propionate and the antimicrobial bambermycin to sheep experimentally infected with E. coli O157:H7 and Salmonella typhimurium. (7/26)

Escherichia coli O157:H7 and Salmonella are widely recognized as important agents of foodborne disease with worldwide distribution. The use of ionophores in feeding growing ruminants is widespread in the United States and has attracted recent interest due to the apparent temporal relationship between initial ionophore use and the increase in human E. coli O157:H7 cases. Two experiments were conducted to evaluate the effects of short-term feeding of ionophores on fecal shedding, intestinal concentrations, and antimicrobial susceptibility of E. coli O157:H7 and S. typhimurium in growing lambs. Sixteen lambs were used in each experiment, four lambs per treatment group: monensin, laidlomycin propionate, bambermycin, and a control treatment. Lambs were fed a grain and hay (50:50) diet with their respective ionophore for 12 d before experimental inoculation with E. coli O157:H7 or S. typhimurium. Animals were maintained on their respective diets an additional 12 d, and fecal shedding of inoculated pathogens was monitored daily. Lambs were killed and tissues and contents were sampled from the rumen, cecum, and rectum. No differences (P > 0.05) in fecal shedding of Salmonella or E. coli O157:H7 were observed due to treatment. Occurrence of Salmonella or E. coli in luminal contents and tissue samples from the rumen, cecum, and rectum did not differ (P > 0.05) among treatments. Feeding monensin decreased (P < 0.05) the incidence of scours in sheep infected with Salmonella compared with the other treatments. No differences in antimicrobial susceptibility were found in any of Salmonella or E. coli O157:H7 isolates. Results from these studies indicate that short-term ionophore feeding had very limited effects on E. coli and Salmonella shedding or on antimicrobial susceptibility in experimentally infected lambs.  (+info)

Influence of flavomycin on ruminal fermentation and microbial populations in sheep. (8/26)

Flavomycin is a phosphoglycolipid antibiotic that promotes growth in ruminants. The aim of this study was to characterize the effects of flavomycin on ruminal micro-organisms and their metabolic consequences. In sheep receiving a mixed grass hay/concentrate diet, inclusion of 20 mg flavomycin day(-1) decreased ruminal ammonia and total volatile fatty acid concentrations (P<0.001), but the acetate : propionate ratio was unchanged. Ruminal pH tended to be lower with flavomycin, and ammonia-production rates of ruminal digesta from control animals measured in vitro tended to be inhibited by flavomycin. Pure-culture studies indicated that anaerobic fungi, protozoa and most bacterial species were insensitive to flavomycin. Fusobacterium necrophorum was the most sensitive species tested, along with some high-activity ammonia-producing (HAP) species. Effects on F. necrophorum in vivo were inconsistent due to large inter-animal variation. HAP numbers appeared to be decreased. Changes in the rumen bacterial-community structure were assessed by using denaturing-gradient gel electrophoresis (DGGE) analysis of rumen digesta 16S rRNA. DGGE profiles differed from animal to animal, but remained consistent from day to day. The community structure changed when flavomycin was introduced. The roles of F. necrophorum and HAP species in ammonia formation and of F. necrophorum in the invasion of wall tissue are consistent with the observed effects of flavomycin on ruminal ammonia formation and, in other studies, on decreasing tissue-turnover rates.  (+info)

Bambermycins are a type of antibiotics that belong to the class of macrolides. They are produced by the bacterium Streptomyces halstedii var. bambergeriensis and consist of a mixture of three components: bambermycin A1, A2, and A3. These antibiotics have been used in veterinary medicine for the treatment of various bacterial infections in animals.

Bambermycins work by binding to the 50S subunit of the bacterial ribosome, which inhibits protein synthesis and ultimately leads to bacterial cell death. They are primarily active against gram-positive bacteria, including some that are resistant to other types of antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA).

However, bambermycins are not approved for use in humans due to concerns about their potential toxicity and the availability of safer and more effective antibiotic options.

Moenomycins A and C are commercially used in the formulation of Bambermycins (Flavomycin), a veterinary antibiotic used solely ...
... bambermycins MeSH D09.698.718.450 - lipopolysaccharides MeSH D09.698.718.450.500 - lipid a MeSH D09.698.718.450.600 - o ...
Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, Lasalocid, and Monensin on the ... Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, Lasalocid, and Monensin on the ... Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, Lasalocid, and Monensin on the ... Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, Lasalocid, and Monensin on the ...
The effect of broiler feed additives flavophospholipol (FPL; Flavomycin, bambermycins) and salinomycin sodium (SAL; Sacox) ... The effect of broiler feed additives flavophospholipol (FPL; Flavomycin, bambermycins) and salinomycin sodium (SAL; Sacox) ...
Moenomycins A and C are commercially used in the formulation of Bambermycins (Flavomycin), a veterinary antibiotic used solely ...
Bambermycins Current Synonym true false 2576138018 Bambermycin Current Synonym true false Associated Value Sets No associated ...
Bambermycin use Bambermycins Bambermycins Bamboo Grass use Sasa Bamboo Grasses use Sasa ...
Bambermycins Preferred Term Term UI T004226. Date01/01/1999. LexicalTag NON. ThesaurusID USAN (1972). ... Bambermycins Preferred Concept UI. M0002165. Registry Number. 11015-37-5. Scope Note. Antibiotic complex obtained from ... Bambermycins. Tree Number(s). D09.698.718.220. Unique ID. D001455. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D001455 ...
Bambermycins Preferred Term Term UI T004226. Date01/01/1999. LexicalTag NON. ThesaurusID USAN (1972). ... Bambermycins Preferred Concept UI. M0002165. Registry Number. 11015-37-5. Scope Note. Antibiotic complex obtained from ... Bambermycins. Tree Number(s). D09.698.718.220. Unique ID. D001455. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D001455 ...
Bambermycins (e.g., bambermycin, flavophospholipol). Beta-Lactams. Penicillins (e.g., penicillin and amoxicillin) ...
C66361 DIK0395679 BALSAM PERU OIL C107269 GX1Q848LV4 BAMALUZOLE C74140 5MZ70CT96H BAMAQUIMAST C72939 PP922A42V2 BAMBERMYCINS ...
Bambermycins and flavophospholipol are used to stop the synthesis of the cell walls of bacteria ...
This included extensive work with Flavomycin (bambermycins), Gainpro (bambermycins), Safe-guard (fenbendazole) and Stenorol ( ...
Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, M?ller A, Poyart C, Akira S, Berner R, Teti G, Geyer A, Hartung T, Trieu-Cuot P, Kasper DL, Golenbock DT. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol. 2005 May 15; 174(10):6449-55 ...
ANTI-INFECTIVE AGENTS BAMBERMYCINS ANTI-INFECTIVE AGENTS BENOMYL ANTI-INFECTIVE AGENTS BENZALKONIUM COMPOUNDS ANTI-INFECTIVE ... ANTIBIOTICS BAMBERMYCINS ANTIBIOTICS BLEOMYCIN ANTIBIOTICS BONGKREKIC ACID ANTIBIOTICS BREFELDIN A ANTIBIOTICS BUTIROSIN ...
T. Delcurto and Earley, A., "Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, ...
T. Delcurto and Earley, A., "Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, ...
T. Delcurto and Earley, A., "Eastern Oregon Agricultural Research Center Annual Report 1998: Comparison of Bambermycins, ...
  • Moenomycins A and C are commercially used in the formulation of Bambermycins (Flavomycin), a veterinary antibiotic used solely in poultry, swine, and cattle feed. (wikipedia.org)
  • This included extensive work with Flavomycin (bambermycins), Gainpro (bambermycins), Safe-guard (fenbendazole) and Stenorol (halofuginone hydrobromide). (feedstrategy.com)